3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Childhood Brain Neoplasm
1
Carcinoma, Medullary
1
Cancer of Lymph Node
1
Bone Neoplasms
1
Adult Brain Glioblastoma
1
Interventions
Irinotecan
6
Temozolomide
5
Cyclophosphamide
5
Vincristine
4
Magnetic Resonance Spectroscopy
4
Doxorubicin
4
palbociclib
3
X-Rays
3
Phantoms, Imaging
3
Gemcitabine
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
ganitumab
2
eribulin
2
cixutumumab
2
cabozantinib
2
abemaciclib
2
Vemurafenib
2
Specimen Handling
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Peripheral Blood Stem Cell Transplantation
2
Nuclear Medicine Department, Hospital
2
Nivolumab
2
LY3023414
2
FANG vaccine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Sarcoma, Ewing
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts